Merrill Garnett





Merrill Garnett (born 4 January 1934) is a biochemist and cancer researcher, and the founder and director of Garnett McKeen Laboratory, Inc. Holding a D.D.S. from New York University, and graduate study in chemistry and biochemistry, Dr. Garnett has had research laboratories at the Central Islip State Hospital, Waldemar Medical Research Foundation, Northport Veterans' Administration Medical Center, and the High Technology Incubator of The State University of New York at Stony Brook.

Dr. Garnett's principal laboratory discoveries reveal the presence of corollary dynamics of the genetic code by which specific DNA coded segments and cell membranes exchange ultra-low frequency sinusoidal electrical currents. According to his theory, these pulsed currents are the basis of all physiological pulses and determine the polarization, charge and folding of enzymes, nucleic acids and membrane phospholipids. The restoration of these charge transfer pathways form the basis of several new methods of medicinal management. Garnett refers to this area of research as Electrogenetics.

Electrogenetics is the basis for designing medicines that can short circuit the electrical charges in cancer cells and produce their selective electrocution. Electrogenetics describes the energy requirements, energy exchanges, and electronic circuits, which allow gene reactions to occur in the living state.

Dr. Garnett then began his search to find a molecular compound that would restore healthy pathways for growth and normal development within the cell-pathways missing or deficient in dysfunctional cells. He searched for a natural metallo-organic compound that would act as a molecular shunt to restore the cells healthy energetics. After testing some 20,000 compounds, Dr. Garnett developed the biochemical formula palladium lipoic acid, a non-toxic chemotherapeutic agent that became available in nutritional supplement form as Poly-MVA in 1991. He discovered that palladium combined with lipoic acid, B-12 and thiamine created an extremely useful and safe cellular nutrient. Dr. Garnett is currently working in cooperation with other researchers to determine the effectiveness of principal ingredients of Poly-MVA for other uses. Investigators at the University of Utah, Columbia University and The State University of New York at Stony Brook have collaborated in studies of this compound. Other new drugs are also under development. Dr. Garnett has been issued three United States patents related to the treatment of tumors and psoriasis.

Garnett wrote a memoir entitled First Pulse: A Personal Journey in Cancer Research (edited by Bill Jones, First Pulse Projects, NY; 1st ed. 1998; 2nd ed. 2001), intended for the non-specialist and non-scientist. It is illustrated with paintings by his daughter Joy Garnett. On the book jacket, his colleague, biochemist Paul Bingham, (Department of Biochemistry & Cell Biology, The State University of New York at Stony Brook) comments:

"Merrill Garnett is a true original--a person in pursuit of a profoundly humane goal along career and personal paths quite unlike anyone else I have ever met. Merrill is one of the rare individuals for whom 'doing well by doing good' isn't a superficial slogan but rather is truly second nature. In this book Merrill has produced a fascinating, intensely personal account of his 40 year quest for effective cancer treatments.I'm sure most readers will react to the book as I did. I was engaged and captivated--both at the personal and at the scientific levels. In this era of bureaucratized science, people like Merrill are increasingly rare and increasingly important. Readers are treated to a deep, clear look into this world."